IRIS

Biomarker-based screening enables early detection of AL amyloidosis in intermediate/high-risk MGUS patients. Our study shows that identifying pre-symptomatic AL through biomarker longitudinal monitoring allows early treatment, leading to significant organ function recovery.

Feasibility of a Biomarker-Based Screening for Pre-Symptomatic AL Amyloidosis in Patients With Intermediate/High-Risk MGUS

Milani, Paolo;Basset, Marco;Nuvolone, Mario;Arcaini, Luca;Palladini, Giovanni
In corso di stampa

Abstract

Biomarker-based screening enables early detection of AL amyloidosis in intermediate/high-risk MGUS patients. Our study shows that identifying pre-symptomatic AL through biomarker longitudinal monitoring allows early treatment, leading to significant organ function recovery.
In corso di stampa
Oncogenesis & Cancer Research
AMERICAN JOURNAL OF HEMATOLOGY
sì
WOS:001369659500001
2-s2.0-85211167165
Esperti anonimi
Inglese
Internazionale
STAMPA
39627959
AL amyloidosis; MGUS; biomarkers; screening
https://onlinelibrary.wiley.com/doi/full/10.1002/ajh.27545
no
13
info:eu-repo/semantics/article
262
Mangiacavalli, Silvia; Milani, Paolo; Cartia, Claudio Salvatore; Varettoni, Marzia; Palumbo, Michele; Basset, Marco; Masoni, Valeria; Nuvolone, Mario;...espandi
1 Contributo su Rivista::1.1 Articolo in rivista
none
1.1 Articolo in rivista
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11571/1514314
Citazioni
  • ???jsp.display-item.citation.pmc??? 2
  • Scopus 5
  • ???jsp.display-item.citation.isi??? 4
social impact